Evgen Pharma Share Discussion Threads

[moneymunch] 18/12/2020 07:05

Good news for SNG...Gla ;-)

- SNG001 given Fast Track designation and IND cleared by the US FDA

- Phase III trial design adapted which will expedite results

- Phase III trial to commence dosing in UK imminently

[moneymunch] 18/12/2020 06:59

Tocilizumab, also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor

[moneymunch] 18/12/2020 06:55

James D Chalmers
@ProfJDChalmers
·
7h
Important data on Tocilizumab in COVID19 just dropped in @NEJM




Reduced progression to requiring mechanical ventilation/death composite but no effect on mortality.

Consistent with earlier trials suggesting reduced ICU admission
There is a signal here

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia | NEJM
Original Article from The New England Journal of Medicine — Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
nejm.org


James D Chalmers
@ProfJDChalmers
·
6h
Two previous trials showed similar trends towards reduced ICU admission but nothing convincing on mortality

REMAP-CAP data apparently positive but not in the public domain
Hard to know if this is just "noise" across multiple trials or real benefit in a subset of patients
Show this thread

[moneymunch] 17/12/2020 18:20

Without doubt bocker, the value of the synthetic production patents and the Sulforadex platform and analogues must be a well and truly massive additional opportunity for transformational upside, the CEO asserted this view in his interview on the manufacturing capabilty / capacity as well as strongly underlining the fact that SFX-01 is the only stabilised, clinical grade, druggable form of sulforaphane, which has a massive range of biological activity associated with multiple disease targets, which is under evaluation by a host of academic research institutes, and so Evgen is very well placed to supply and develop SFX-01 and its analogues for any clinical trial and ready for any commercial scenario, several of which could be in the pipeline. Gl ;-)


10/12/20

-- To ensure our selected development programmes meet stringent scientific and commercial criteria

-- Our core R&D efforts to be focused on our oncology and ARDS pipeline

-- SFX-01 to continue to be provided to academic groups for preclinical evaluation in selected disease models

-- Consideration will be given to supporting clinical evaluation of SFX-01 in non-core indications where there is compelling preclinical data and an attractive commercial opportunity

-- To leverage the Sulforadex(R) platform by supporting Juvenescence in bringing products to market outside the pharmaceutical sector

-- The business model is to establish proof of concept and then conclude partnerships.


NON-CLINICAL PROGRAMMES

Our long-term toxicology and manufacturing process development work has continued. Initial data suggest that we will be able to demonstrate an acceptable toxicology profile for conducting clinical trials in chronic diseases where longer term dosing is required. These data are consistent with our observations of patients who received SFX-01 for extended periods in the mBC trial.

Scale-up of our formulation and manufacturing processes has progressed. In particular, a commercial scale process for producing a key intermediate in drug substance manufacture has been developed by a well-regarded contract manufacturing organisation. Also, the stabilised sulforaphane conjugate has demonstrated good flow properties in prototype solid dose formulations, enabling larger scale production.

[bumpa33] 17/12/2020 18:15

It is barking mad Wan, ridiculous in fact. But then that’s why we’re here.

[wanobi] 17/12/2020 18:13

13m MCAP is barking Mad to me,,,, when you look at those US MCAP's tis nuts,,, wonder if our new CEO will be looking across the pond,,,, already is Wan I hear you say :-) LOL,,,, GLA Holders, Cheers Wan :-)

[bumpa33] 17/12/2020 18:09

Yes, there are quite a number bocker01.

And the beauty of it is all the information on sulforaphane is already out there in the public domain.

[bocker01] 17/12/2020 18:04

Endless opportunities just amazing!

[bumpa33] 17/12/2020 17:58

SFX-01 is a synthesized, stabilized and concentrated form of Sulforaphane, a sort of premium formulation of its base constituent if you like?

If one of those many ‘shots on goal’ - as Huw put it - goes in, the hype over sulforaphane/SFX-01 will go into orbit. I hope that the new CEO will push us forward in partnering with many others in the “sulforaphane as a panacea treatment” arena, with SFX-01 seen as the only choice (in sulforaphane based clinical trials) and effectively giving us yet more of those ‘shots’.

And yet still, the valuation in terms of R/R is rock bottom. For now.

[bocker01] 17/12/2020 17:27

Yes Bumper. What I do not understand is the value of synthetic production patents. We are looking at the value of this share based on its own SFX product stream. However as Money keeps pointing out there are other therapeutic uses for sulforaphane being investigated. It’s too unstable to commercialise in its natural form though. Does that mean that that we may also become the only port of call either to manufacture under license, license to manufacture or sell synthetic sulforaphane for those applications? If so that seems to me to be a massive additional opportunity. Have I missed my turning and gone doolally or this likely possibility? Money what do you think?

[bumpa33] 17/12/2020 14:37

Interesting, something I missed from the interview first time round - the upping of investment In manufacturing capability/capacity - in the year just gone and the year ahead. Clearly anticipating increasing demand.

[moneymunch] 16/12/2020 21:51

Ps Miracle treatment!!!!...:-)))

[moneymunch] 16/12/2020 21:38

I think the following could be our new target and collaboration...Gl :-)

"Sulforaphane is a naturally occurring Nrf2 activator noted for its anti-inflammatory mechanisms and ability to quickly cross the blood-brain-barrier. "


..........................

Nanoparticles create ‘miracle’; treatment for deadly brain tumors

10/11/20

ANN ARBOR, Mich. — For scientists treating diseases in the brain, crossing the body’s natural barriers to this organ is the most difficult task to complete. Now, scientists at the University of Michigan say nanoparticles are allowing them to break through the nearly impenetrable blood-brain barrier. The achievement is giving cancer researchers the opportunity to deliver a new and game-changing drug to kill brain tumors.

Glioblastoma is the most common and deadliest form of brain cancer in adults. Cases of the illness continue to rise in several countries. The average survival length for patients with glioblastoma is about 18 months. Less than five percent of patients live longer than five years after their diagnosis.

The nanoparticle breakthrough delivers medication intravenously into the patient. These particles, which house the cancer cell-killing drug, are able to slip past the blood-brain barrier and target malignant tumors forming in the brain.

Along with a combination of radiation, the Michigan team says seven of eight mice given this treatment survived their cancers. More importantly, when those seven mice had a recurrence of glioblastoma, their immune systems prevented the cancer from growing back. Each mouse was able to do this without needing further treatments or radiation.

“It’s still a bit of a miracle to us,” says co-senior author Joerg Lahann in a university release. “Where we would expect to see some levels of tumor growth, they just didn’t form when we rechallenged the mice. I’ve worked in this field for more than 10 years and have not seen anything like this.”
Teaching the body how to beat cancer

Researchers say infusing nanoparticles with cancer drugs not only delivered a lethal blow to the main brain tumor, but also helped the patient’s immune system to recognize and attack cancer cells.

“This is a huge step toward clinical implementation,̶1; says study co-author Maria Castro. “This is the first study to demonstrate the ability to deliver therapeutic drugs systemically, or intravenously, that can also cross the blood-brain barrier to reach tumors.”

Castro adds she’s known for five years how she wanted to attack brain cancer, but needed a way to do it. The R.C. Schneider Collegiate Professor of Neurosurgery says her approach stops a specific signal cancer cells broadcast. This signal, STAT3, tricks immune cells into letting cancer inside the patient’s brain.

Castro’s treatment inhibits STAT3, allowing the immune system to eliminate cancer cells which are now exposed to the body’s defenses. The only catch was developing a method to safely get this inhibitor beyond the blood-brain barrier.
How nanoparticles attack brain tumors

Castro consulted with Lahann’s team in the university’s Biointerfaces Institute and began working on a nanoparticle delivery system. Study authors say a protein called human serum albumin is one of the few molecules in blood that successfully crosses the barrier.

The protein became the building block for the new nanoparticles, which utilize synthetic molecules to link the human serum albumins. The team then attached the STAT3 inhibitor and a peptide called iRGD. This compound acts as a tumor homing device for the cancer-killing nanoparticles.

Mice in the initial study received several doses of the nano-prescription over three weeks. The results reveal that mice responding to the treatment saw their survival length jump from 28 days to 41 days. The Michigan team’s second study added radiation therapy to the mix. It’s in this trial where the seven of eight mice made it through and were diagnosed tumor-free.

Researchers are hoping their synthetic protein nanoparticles will soon provide doctors with a new option for destroying currently “undruggable” tumors.

[bocker01] 16/12/2020 20:21

Yes the Welshman knows his leeks. I think we’ve now got a far greater focus on commercialisation! Came across extremely well, astute, articulate and thoughtful. Clearly very much excited about the solid tumour development. Made it clear that we are the guys who can mass produce the product which I guess means that successful research done elsewhere into sulforaphane ends up with us if a scaled up synthetic commercial product is required.

[moneymunch] 16/12/2020 19:15

A very impressive delivery from the new CEO, which now paves the way for a flow of potential good news on their disease target pipeline and possibly Transformational good news with a high chance of commercial JV partnership on several fronts, and interim news on the first 100 patients administered SFX-01 for the Covid-19 trials, recruited and assessed , could be rapidly approaching....it took Prof Chalmers only 17 days to recruit the first 100 patients to his Stop-Covid patient trials, all of which had to be hospitalised and confirmed Covid positive, whereas SFX-01 recruitment is from patients displaying Ards/pneumonia symptoms regardless of testing positive....Gla holders...a major re-rate ot two, very likely....and positive indications from the Covid-19 patient trials will see this multi-bag from this ridiculously low market cap. :-)

[lovewinshatelosses] 16/12/2020 16:04

Just watched it. Yes indeed, hopefully a sign of things to come on the marketing front, to finally get us proper exposure and some new investors onboard, to drive share price growth, while the various irons in the fire progress.
I might buy some more later this week. GLA.

[daftweejock] 16/12/2020 11:50

Ah ok thanks

[bumpa33] 16/12/2020 11:26

it was an uncrossing trade - part of the daily auction processes.

[daftweejock] 16/12/2020 11:11

Was that sell order holding us back you think? Anyways gone now

[bumpa33] 16/12/2020 09:49

Yes mm, nice to see the CEO in the flesh finally and thought he came across very well. I hope this marks the start of a better/more forthcoming PR strategy. No point having potential if nobody bloody knows about it.

[moneymunch] 16/12/2020 09:42

A great interview and very well delivered by our new CEO, and very bullish indeed Bumpa and exciting times for all invested going forward. Gla :-)

Ps "the best pre-clinical data seen on the hard to treat solid tumour target, very exciting data", and were still awaiting disclosure of who their collaboration partner is....which will happen on patent filing and scientific paper preparation....which suggests a commercial player rather than academic imho...:-)

[daftweejock] 16/12/2020 09:40

Lol yup, thanks was listening in car couldnt take notes

[bumpa33] 16/12/2020 09:35

Exert...

“some of the best pre-clinical data we’ve seen in terms of shrinking a very difficult to treat tumor and extending survival, pre-clinically...221;

I guess at some point they’ll be telling the market more/officially about this new ‘small’ development...!